Melanoma Drugs Global Market Report 2024

The melanoma drugs market has grown rapidly in recent years. It will grow from $8.27 billion in 2023 to $9.27 billion in 2024 at a compound annual growth rate (CAGR) of 12.1%. The growth observed in the historical period can be credited to advances in clinical research, heightened incidence rates, shifts in the treatment landscape, enhanced diagnostic techniques, and regulatory approvals.

The melanoma drugs market is expected to see rapid growth in the next few years. It will grow to $13.98 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The anticipated growth in the forecast period can be attributed to advancements in immunotherapy, ongoing biomarker research, the aging global population, the expansion of markets in emerging economies, and collaborative research initiatives. Notable trends in this forecast period include innovations in adjuvant therapies, increased utilization of checkpoint inhibitors, strategies for patient stratification, integration of real-world evidence, and global collaborations in clinical trials.

The anticipated increase in melanoma incidence among males is set to drive the growth of the melanoma drug market in the coming years. Melanoma, a form of skin cancer originating in pigment-regulating cells (melanocytes), is treated using medications specifically designed for melanoma, aiming to target and inhibit the growth and spread of melanoma cells within the body. The rising incidence of melanoma is expected to elevate the demand for melanoma drugs. In 2023, the American Cancer Society, Inc. reported a rise in new cases among male individuals in the United States, increasing from 57,180 in 2022 to 58,120 in 2023. Consequently, the surge in melanoma cases among males is a key driver propelling the growth of the melanoma drug market.

The increasing aging population is poised to propel the growth of the melanoma drug market in the future. An aging population trend refers to a demographic shift characterized by a growing proportion of elderly individuals within a society. Melanoma drugs play a crucial role in addressing skin cancer concerns and improving treatment outcomes in the elderly. As of October 2022, the World Health Organization projected that by 2030, 1 in 6 individuals globally would be 60 years old or older. During this period, the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion. Additionally, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion by 2050. Hence, the expanding aging population is a significant driver of the melanoma drug market.

Product innovation stands out as a notable trend gaining momentum in the melanoma drugs market. Major companies within the market are concentrating their efforts on developing innovative solutions to solidify their market position. For example, in March 2022, the U.S. Food and Drug Administration (FDA) approved Opdualag, a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab, developed by Bristol-Myers Squibb Company. This approval is for the treatment of melanoma in both adult and pediatric patients. Opdualag combines the antibodies relatlimab and nivolumab at a fixed dose, offering a breakthrough approach. Adult and adolescent patients aged 12 and older, weighing at least 40 kg, are recommended to receive 480 mg of nivolumab and 160 mg of relatlimab intravenously every four weeks until disease progression or unacceptable toxicity occurs.

Major companies in the melanoma drug market are prioritizing the development of breakthrough therapies, such as T cell receptor (TCR) therapeutics, to treat uveal melanoma and gain a competitive advantage. TCR therapeutics involve using engineered T cell receptors to redirect the immune system to recognize and target specific antigens, particularly in the context of cancer. For instance, in January 2022, Immunocore, a UK-based biotechnology company, received FDA approval for KIMMTRAK, the first FDA-approved therapy for unresectable or metastatic uveal melanoma. This TCR therapeutic demonstrated significant overall survival benefits in clinical trials, with a median OS of nearly 22 months. The approval marks several milestones, including being the first TCR therapeutic to receive FDA approval and the first bispecific T cell engager approved for the treatment of solid tumors.

In May 2022, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, completed the acquisition of Checkmate Pharmaceuticals Inc. for $250 million. This strategic move aims to expand Regeneron Pharmaceuticals Inc.'s pipeline portfolio of immuno-oncology drugs and provide a new modality to treat challenging cancers. Checkmate Pharmaceuticals, Inc., a US-based biopharmaceutical company, specializes in mutant metastatic melanoma.

Major companies operating in the melanoma drugs market report are Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche A, GlaxoSmithKline plc, Janssen Biotech Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Genentech Inc., Merck & Co. Inc., Bayer AG, Bausch Health Companies Inc., Cipla Limited, Vical Incorporated, Aduro Biotech Inc., OSE Immunotherapeutics, Daiichi Sankyo Company Limited, Gilead Sciences, Seagen Inc., Incyte Corporation, Kyowa Kirin Co. Ltd., Almirall S.A., MacroGenics Inc., Prometheus Biosciences Inc., Fortress Biotech Inc., OncoSec Medical Incorporated, Regeneron Pharmaceuticals Inc., Iovance Biotherapeutics.

North America was the largest region in the melanoma drugs market in 2023. The regions covered in the melanoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the melanoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary therapeutic approaches for melanoma drugs include chemotherapy, immunotherapy, and targeted therapy. Chemotherapy is a medical intervention utilizing drugs to either destroy or impede the growth of cancer cells. It stands as a key treatment option for cancer and is typically combined with other modalities such as surgery and radiation therapy. Melanoma drugs find application in treating various melanoma types, including superficial spreading melanoma, lentigo maligna, acral lentiginous melanoma, and nodular melanoma, in settings such as hospitals, outpatient oncologist clinics, and others.

The melanoma drugs market research report provides melanoma drugs market statistics, including melanoma drugs industry global market size, regional shares, competitors with a melanoma drugs market share, detailed melanoma drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the melanoma drugs industry. This melanoma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The melanoma drug market consists of sales of pembrolizumab, nivolumab, vemurafenib, avelumab, and dabrafenib with trametinib drugs used for the treatment of melanoma. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.